Professor of Medicine, Epidemiology and International Health
The Johns Hopkins University
- Tuberculosis and HIV
Dr Chaisson's research interests focus on tuberculosis and HIV infection, including global epidemiology and control, prevention, and clinical and public health interventions. He is currently Principal Investigator for 11 research grants, and is Principal Investigator of the Consortium to Respond Effectively to the AIDS/TB Epidemic (CREATE), an international research consortium funded by the Bill and Melinda Gates Foundation to assess the impact of novel strategies for controlling HIV-related TB. He has published more than 300 scientific papers and book chapters.
- World Health Organization/STOP TB Scientific and Technical Advisory Group
- Consortium to Respond Effectively to the AIDS/TB Epidemic (CREATE), Principal Investigator
- Conference on Retroviruses and Opportunistic Infections Program Committee
- University of Massachusetts, BS, summa cum laude (1976)
- University of Massachusetts Medical School, MD (1982)
- University of California San Francisco, Intern in Internal Medicine (1982-1983)
- University of California San Francisco, Junior Resident in Internal Medicine, Primary Care, Moffitt Hospital (1983-1984)
- University of California San Francisco, Senior Resident in Internal Medicine, Primary Care, San Francisco General Hospital (1984-1985)
- University of California San Francisco, Scholar, Clinical Epidemiology Program, Fellow, Infectious Diseases, Department of Medicine and Epidemiology and International Health (1985)
- Chaisson RE, Schecter GF, Theuer CP, Rutherford GW, Echenberg DF, Hopewell PC. Tuberculosis in patients with the acquired immunodeficiency syndrome. Clinical features, response to therapy, and survival. Am Rev Respir Dis. 1987;136:570-574.
- Chaisson RE, Bacchetti P, Osmond D, Brodie B, Sande MA, Moss AR. Cocaine use and HIV infection in intravenous drug users in San Francisco. JAMA. 1989;261:561-565.
- Gallant JE, Moore RD, Chaisson RE. Prophylaxis for opportunistic infections in patients with HIV infection. Ann Intern Med. 1994;120:932-944.
- Chaisson RE, Benson CA, Dube MP, Heifets LB, Korvick JA, Elkin S, Smith T, Craft JC, Sattler FR. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS. AIDS Clinical Trials Group Protocol 157 Study Team. Ann Intern Med. 1994;121:905-911.
- Chaulk CP, Moore-Rice K, Rizzo R, Chaisson RE. Eleven years of community-based directly observed therapy for tuberculosis. JAMA. 1995;274:945-951.
- Chaisson RE, Keruly JC, Moore RD. Race, sex, drug use, and progression of human immunodeficiency virus disease. N Engl J Med. 1995;333:751-756.
- Chaisson RE, Clermont HC, Holt EA, Cantave M, Johnson MP, Atkinson J, Davis H, Boulos R, Quinn TC, Halsey NA. Six-month supervised intermittent tuberculosis therapy in Haitian patients with and without HIV infection. Am J Respir Crit Care Med. 1996;154:1034-1038.
- Halsey NA, Coberly JS, Desormeaux J, Losikoff P, Atkinson J, Moulton LH, Contave M, Johnson M, Davis H, Geiter L, Johnson E, Huebner R, Boulos R, Chaisson RE. Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet. 1998;351:786-792.
- De Cock KM, Chaisson RE. Will DOTS do it? A reappraisal of tuberculosis control in countries with high rates of HIV infection. Int J Tuberc Lung Dis. 1999;3:457-465.
- Morris L, Martin DJ, Bredell H, Nyoka SN, Sacks L, Pendle S, Page-Shipp L, Karp CL, Sterling TR, Quinn TC, Chaisson RE. Human immunodeficiency virus-1 RNA levels and CD4 lymphocyte counts, during treatment for active tuberculosis, in South African patients. J Infect Dis. 2003;187:1967-1971.